India’s Cipla: ‘Huge wave’ of pandemic-driven interest in health and wellness

CNBC International’s Tanvir Gill and Nancy Hungerford interact with Umang Vohra to discuss the company’s performance, play in COVID-19 and future outlook and plans. Umang talks about how only 5% of the company’s sales come from Remdesivir and the COVID related portfolio, and that the company is also doing incredibly well beyond the COVID portfolio. The conversation highlights how Cipla is the No. 2 seller of respiratory devices across the world and is seeing very strong momentum in the lung therapy as lung leaders of the world, as well as in other therapies.

Source credit: Interview appeared on CNBC International's Street Signs Asia show

Cipla ropes in Ayushmann Khurrana for #BerokZindagi campaign

We have launched the third chapter of the campaign to dispel myths about asthma and normalize the use of inhalers.

Cipla stands strong with India in the battle against COVID-19

News: Cipla announced a INR 25 crore fund to support the Indian Government’s efforts to effectively combat the COVID-19 pandemic. This includes a voluntary donation of approximately INR 3 crore from Cipla employees who have stepped forward in this hour of national need. Through its wide-ranging relief efforts, the Company is focusing on initiatives that have the maximum impact and reach. It is currently supporting public health institutions, frontline healthcare workers, vulnerable patients and communities struggling in the aftermath.


Cipla: Breath of new air

Structural changes in the global pharma industry are throwing up challenges and opportunities. Enter Cipla with its expertise in medicine, and vision for relevance beyond pharma.

Employee stories

Hear it from the Cipla-ites!

Anoop V K
ALIVE B-School Summer Intern 2018, Finance

“8 weeks, 4 projects, 2 new countries and an amazing experience. I am happy to have taken the baby steps in my management career at Cipla.  I was overwhelmed by the trust that my project guide and owner put in me. I am thankful to Cipla for giving me the opportunity to spend my summer as an intern here.”

Anoop V K

ALIVE B-School Summer Intern 2018, Finance

“Cipla is a 83-year old start-up.  We are in midst of a very exciting transformation journey at Cipla and every day is a unique challenge: working on multiple game changing projects in HR to solve the toughest problems, keeps us on our toes all the time.  One year in Cipla has been a roller coaster ride: my role has changed three times in a year and the excitement continues!”

Anupam Hans

Director, Talent Acquisition

“For me, Cipla is a land of opportunities. Over last 3.5 years of being with the Company, I have worked across 4 very different roles - from Business Finance to M&A to now leading the Global CFO’s Office and Investor Relations for the Company. I believe that at Cipla, it is potential which matters more than experience.”

Naveen Bansal

Associate Director, Global CFO’s Office and Investor Relations

Business Highlights

Business Highlights

Our investments in manufacturing capital include development of new drug delivery systems, facilitation of infrastructure supporting API and formulation developments and strengthening of platform technologies.

Building a healthy world
About Manufacturing Facility

state-of-the-art manufacturing facilities across 5 countries

Fighting global diseases
Fighting global diseases

dosage forms and 1,500+ products


global employees


scientists and 6 R&D facilities

4 Lakh+

healthcare professionals and 3.5 lakh+ pharmacists

Cipla Foundation

With Cipla Foundation, we envision and execute Cipla’s Corporate Social Responsibility. In the last year, we have reached out to over 2,20,000 individuals in the community across in Health, Education, Skilling and Disaster Response.



Support replicable and scalable models towards sustainable change.



Generate evidence, knowledge and skilled workforce in our chosen domains.


Disaster Management

Support to communities affected by disasters.



Sparking the curiosity for learning.